5 results on '"Hoffmann, Markus"'
Search Results
2. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.
- Author
-
Hoffmann, Markus, Krüger, Nadine, Schulz, Sebastian, Cossmann, Anne, Rocha, Cheila, Kempf, Amy, Nehlmeier, Inga, Graichen, Luise, Moldenhauer, Anna-Sophie, Winkler, Martin S., Lier, Martin, Dopfer-Jablonka, Alexandra, Jäck, Hans-Martin, Behrens, Georg M.N., and Pöhlmann, Stefan
- Subjects
- *
SARS-CoV-2 , *COVID-19 pandemic , *VIRAL proteins , *IMMUNOGLOBULINS , *VIRAL mutation , *PUBLIC health - Abstract
The rapid spread of the SARS-CoV-2 Omicron variant suggests that the virus might become globally dominant. Further, the high number of mutations in the viral spike protein raised concerns that the virus might evade antibodies induced by infection or vaccination. Here, we report that the Omicron spike was resistant against most therapeutic antibodies but remained susceptible to inhibition by sotrovimab. Similarly, the Omicron spike evaded neutralization by antibodies from convalescent patients or individuals vaccinated with the BioNTech-Pfizer vaccine (BNT162b2) with 12- to 44-fold higher efficiency than the spike of the Delta variant. Neutralization of the Omicron spike by antibodies induced upon heterologous ChAdOx1 (Astra Zeneca-Oxford)/BNT162b2 vaccination or vaccination with three doses of BNT162b2 was more efficient, but the Omicron spike still evaded neutralization more efficiently than the Delta spike. These findings indicate that most therapeutic antibodies will be ineffective against the Omicron variant and that double immunization with BNT162b2 might not adequately protect against severe disease induced by this variant. [Display omitted] • Omicron uses human and animal ACE2 for host cell entry • Omicron is resistant against neutralization by several therapeutic antibodies • Omicron efficiently evades antibodies from infected or 2 × BNT-vaccinated patients • Omicron moderately evades antibodies induced by 3 × BNT or heterologous vaccination The SARS-CoV-2 Omicron variant is rapidly spreading worldwide and a public health concern. Experiments show that this variant is resistant against several therapeutic antibodies for COVID-19 and efficiently evades antibodies induced upon infection or double BNT162b2 vaccination, but not triple BNT162b2 or ChAdOx1/BNT162b2 vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies.
- Author
-
Hoffmann, Markus, Arora, Prerna, Groß, Rüdiger, Seidel, Alina, Hörnich, Bojan F., Hahn, Alexander S., Krüger, Nadine, Graichen, Luise, Hofmann-Winkler, Heike, Kempf, Amy, Winkler, Martin S., Schulz, Sebastian, Jäck, Hans-Martin, Jahrsdörfer, Bernd, Schrezenmeier, Hubert, Müller, Martin, Kleger, Alexander, Münch, Jan, and Pöhlmann, Stefan
- Subjects
- *
SARS-CoV-2 , *CONVALESCENT plasma , *COVID-19 pandemic , *COVID-19 treatment , *COVID-19 - Abstract
The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the COVID-19 pandemic. However, the recently emerged SARS-CoV-2 variants B.1.1.7 (UK), B.1.351 (South Africa), and P.1 (Brazil) harbor mutations in the viral spike (S) protein that may alter virus-host cell interactions and confer resistance to inhibitors and antibodies. Here, using pseudoparticles, we show that entry of all variants into human cells is susceptible to blockade by the entry inhibitors soluble ACE2, Camostat, EK-1, and EK-1-C4. In contrast, entry of the B.1.351 and P.1 variant was partially (Casirivimab) or fully (Bamlanivimab) resistant to antibodies used for COVID-19 treatment. Moreover, entry of these variants was less efficiently inhibited by plasma from convalescent COVID-19 patients and sera from BNT162b2-vaccinated individuals. These results suggest that SARS-CoV-2 may escape neutralizing antibody responses, which has important implications for efforts to contain the pandemic. [Display omitted] • B.1.1.7, B.1.351, and P.1 do not show augmented host cell entry • Entry inhibitors under clinical evaluation block all variants • B.1.351 and P.1 can escape from therapeutic antibodies • B.1.351 and P.1 evade antibodies induced by infection and vaccination Comparison of the SARS-CoV-2 variants B.1.1.7, B.1.351, and P.1 shows that inhibitors under clinical evaluation are still effective in blocking entry, though the B.1.351 and P.1 variants evade antibody responses induced upon infection as well as vaccination and evade certain therapeutic antibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
- Author
-
Hoffmann, Markus, Kleine-Weber, Hannah, Schroeder, Simon, Krüger, Nadine, Herrler, Tanja, Erichsen, Sandra, Schiergens, Tobias S., Herrler, Georg, Wu, Nai-Huei, Nitsche, Andreas, Müller, Marcel A., Drosten, Christian, and Pöhlmann, Stefan
- Subjects
- *
COVID-19 , *PROTEASE inhibitors , *VIRAL transmission , *SARS virus - Abstract
The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention. • SARS-CoV-2 uses the SARS-CoV receptor ACE2 for host cell entry • The spike protein of SARS-CoV-2 is primed by TMPRSS2 • Antibodies against SARS-CoV spike may offer some protection against SARS-CoV-2 The emerging SARS-coronavirus 2 (SARS-CoV-2) threatens public health. Hoffmann and coworkers show that SARS-CoV-2 infection depends on the host cell factors ACE2 and TMPRSS2 and can be blocked by a clinically proven protease inhibitor. These findings might help to establish options for prevention and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
- Author
-
Wrapp, Daniel, De Vlieger, Dorien, Corbett, Kizzmekia S., Torres, Gretel M., Wang, Nianshuang, Van Breedam, Wander, Roose, Kenny, van Schie, Loes, Hoffmann, Markus, Pöhlmann, Stefan, Graham, Barney S., Callewaert, Nico, Schepens, Bert, Saelens, Xavier, and McLellan, Jason S.
- Subjects
- *
CELL receptors , *SARS-CoV-2 , *COVID-19 , *IMMUNOGLOBULINS , *MEMBRANE fusion , *BETACORONAVIRUS - Abstract
Coronaviruses make use of a large envelope protein called spike (S) to engage host cell receptors and catalyze membrane fusion. Because of the vital role that these S proteins play, they represent a vulnerable target for the development of therapeutics. Here, we describe the isolation of single-domain antibodies (VHHs) from a llama immunized with prefusion-stabilized coronavirus spikes. These VHHs neutralize MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. Crystal structures of these VHHs bound to their respective viral targets reveal two distinct epitopes, but both VHHs interfere with receptor binding. We also show cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrate that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. These data provide a molecular basis for the neutralization of pathogenic betacoronaviruses by VHHs and suggest that these molecules may serve as useful therapeutics during coronavirus outbreaks. • VHHs isolated from a llama immunized with prefusion-stabilized coronavirus spikes • Structural characterization of VHHs reveals conserved mechanism of neutralization • SARS-CoV-1 S-directed VHH cross-reacts with SARS-CoV-2 S • Bivalent VHH neutralizes SARS-CoV-2 pseudoviruses Using llamas immunized with prefusion-stabilized betacoronavirus spike proteins, Wrapp et al. identify neutralizing cross-reactive single-domain camelid antibodies, which may serve not only as useful reagents for researchers studying the viruses causing MERS, SARS, and COVID-19, but also potential therapeutic candidates. Crystal structures further reveal how these antibodies bind spike proteins to prevent virus entry into cells. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.